0001415889-23-013899.txt : 20231003
0001415889-23-013899.hdr.sgml : 20231003
20231003170050
ACCESSION NUMBER: 0001415889-23-013899
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230929
FILED AS OF DATE: 20231003
DATE AS OF CHANGE: 20231003
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Ben Zvi Shmuel
CENTRAL INDEX KEY: 0001935668
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-33357
FILM NUMBER: 231305050
MAIL ADDRESS:
STREET 1: 2 SNUNIT STREET
STREET 2: SCIENCE PARK, #455
CITY: CARMIEL
STATE: L3
ZIP: 2161401
FORMER NAME:
FORMER CONFORMED NAME: Zvi Shmuel Ben
DATE OF NAME CHANGE: 20220628
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Protalix BioTherapeutics, Inc.
CENTRAL INDEX KEY: 0001006281
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 650643773
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 2 UNIVERSITY PLAZA
STREET 2: SUITE 100
CITY: HACKENSACK
STATE: NJ
ZIP: 07601
BUSINESS PHONE: 201-696-9345
MAIL ADDRESS:
STREET 1: 2 UNIVERSITY PLAZA
STREET 2: SUITE 100
CITY: HACKENSACK
STATE: NJ
ZIP: 07601
FORMER COMPANY:
FORMER CONFORMED NAME: ORTHODONTIX INC
DATE OF NAME CHANGE: 19980422
FORMER COMPANY:
FORMER CONFORMED NAME: EMBASSY ACQUISITION CORP
DATE OF NAME CHANGE: 19960124
4
1
form4-10032023_051016.xml
X0508
4
2023-09-29
0001006281
Protalix BioTherapeutics, Inc.
PLX
0001935668
Ben Zvi Shmuel
C/O PROTALIX BIOTHERAPEUTICS, INC.
2 SNUNIT STREET SCIENCE PARK, POB 455
CARMIEL
L3
2161401
ISRAEL
true
false
false
false
0
Stock Option (Right to Buy)
1.66
2023-09-29
4
A
0
61676
0
A
2033-09-29
Common Stock
61676
61676
D
The shares of common stock underlying the stock options shall vest in 12 equal quarterly installments commencing upon the date of grant. The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Protalix BioTherapeutics, Inc., Amended and Restated 2006 Stock Incentive Plan, as amended.
Does not include (i) options to purchase 40,000 shares of common stock at an exercise price equal to $1.09 per share that expire on June 30, 2032 and (ii) options to purchase 10,000 shares of common stock at an exercise price equal to $1.03 per share that expire on September 7, 2032.
/s/ Eyal Rubin, Attorney-in-Fact
2023-10-03